Adjuvant olaparib real world data for BRCA positive, HER2-negative high-risk early breast cancer patients in the United Kingdom
{{output}}
IntroductionSince 2023 olaparib has been commissioned in the United Kingdom for breast cancer for patients with breast cancer gene 1 and 2 (BRCA1 and 2) positive, human epidermal growth factor receptor 2 (HER2)-negative, high-risk early disease after chemother... ...
